Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase

2015

Background & Aims: Plasma levels of high-density lipoprotein (HDL) cholesterol are frequently found decreased in patients with inflammatory bowel disease (IBD). Therefore, and because HDL exerts anti-inflammatory activities, we investigated whether HDL and its major protein component apolipoprotein A-I (apoA-I) modulate mucosal inflammatory responses in vitro and in vivo. Methods: The human intestinal epithelial cell line T84 was used as the in vitro model for measuring the effects of HDL on the expression and secretion of tumor necrosis factor (TNF), interleukin-8 (IL-8), and intracellular adhesion molecule (ICAM). Nuclear factor-κB (NF-κB)-responsive promoter activity was studied by …

WT wild typeApolipoprotein BEMSA electrophoretic mobility shift assayMPO myeloperoxidaseIκB kinaseDSS dextran sodium sulphatemTOR the mammalian target of rapamycinRT-PCR real-time polymerase chain reactionNF-κBchemistry.chemical_compound540 ChemistryApoA-I apolipoprotein A-I10038 Institute of Clinical ChemistryOriginal ResearchTNF tumor necrosis factorbiologyIBD inflammatory bowel diseaseChemistryGastroenterologyMyeloperoxidase10076 Center for Integrative Human PhysiologyMEICS murine endoscopic index of colitis severityTumor necrosis factor alphalipids (amino acids peptides and proteins)3-MA 3-methyl adenineNF-κB nuclear factor κBHDL high-density lipoproteinLC3II light chain 3 IIPBS phosphate-buffered salinep-IKK phosphorylated IκB kinase610 Medicine & healthICAM intracellular adhesion molecule246-Trinitrobenzenesulfonic acidTg transgenicmedicineAutophagyCD Crohn’s disease2715 GastroenterologyColitislcsh:RC799-869KO knockoutHepatologyApolipoprotein A-IAutophagyInflammatory Bowel DiseaseTNBS 246-trinitrobenzenesulfonic acidmedicine.diseaseMolecular biologyIL interleukinsiRNA small interfering RNAPI-3 phosphatidylinositol-3Immunologybiology.protein2721 Hepatologylcsh:Diseases of the digestive system. GastroenterologyPFA paraformaldehydeLipoproteinDAPI 4′6-diamidino-2-phenylindoleCMGH Cellular and Molecular Gastroenterology and Hepatology
researchProduct

Losing weight after menopause with minimal aerobic training and mediterranean diet

2020

Objective: It is a common belief that menopausal women have greater difficulty losing weight. The aim of this study was to assess the efficacy of a Mediterranean diet (MD) to promote weight loss in postmenopausal women. All participants were prescribed a hypocaloric traditional MD, tailored to the individual. Subjects were asked not to begin any kind of physical activity. Body composition was measured at the beginning and after 8 weeks of treatment. In total, 89 women (age 52.8 &plusmn

Weight lossMediterranean dietPhysiology030209 endocrinology & metabolismlcsh:TX341-641Diet MediterraneanPlant Proteins DietarySettore MED/49Body compositionArticle03 medical and health sciences0302 clinical medicineSettore MED/13Weight lossMediterranean dietAnimal Proteins DietaryMass variationHumansMedicineAerobic exerciseNutritional Physiological Phenomena030212 general & internal medicineExerciseNutrition and Dieteticsbusiness.industryMetabolic riskAge FactorsMiddle AgedChronic degenerative diseasesmedicine.diseaseLipoproteins LDLWeight Reduction ProgramsMenopauseBlood pressureAdipose TissueHeart Disease Risk FactorsFemalemedicine.symptomMenopausebusinesslcsh:Nutrition. Foods and food supplyFood ScienceLipoprotein
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct

Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.

2014

Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs influence…

adipose tissue adipokines obesity lipoproteins
researchProduct

Emerging Therapies For Raising Hdl-C And Augmenting Hdl Particle Functionality

2013

High-density lipoprotein particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wall inju…

apoA-I mimetic coronary artery disease delipidation endothelial lipase inhibitor farnesoid X receptor high-density lipoproteins liver X receptor reverse cholesterol transport RVX-208
researchProduct

The pathophysiology of intestinal lipoprotein production

2015

Intestinal lipoprotein production is a multistep process, essential for the absorption of dietary fats and fat-soluble vitamins. Chylomicron assembly begins in the endoplasmic reticulum with the formation of primordial, phospholipids-rich particles that are then transported to the Golgi for secretion. Several classes of transporters play a role in the selective uptake and/or export of lipids through the villus enterocytes. Once secreted in the lymph stream, triglyceride-rich lipoproteins (TRLs) are metabolized by Lipoprotein lipase (LPL), which catalyzes the hydrolysis of triacylglycerols of very low density lipoproteins (VLDLs) and chylomicrons, thereby delivering free fatty acids to vario…

assemblyVery low-density lipoproteinSettore MED/09 - Medicina InternaPhysiologyBlood lipidsReviewBiologyTriglyceride-rich lipoproteininherited disorderslcsh:Physiologysymbols.namesakePhysiology (medical)Lipoprotein lipaselcsh:QP1-981Endoplasmic reticulumdigestive oral and skin physiologytrygliceride-rich lipoproteinschylomicronAssembly; Chylomicron; Inherited disorders; Secretion; Triglyceride-rich lipoproteins; Physiology; Physiology (medical)Golgi apparatussecretionChylomicron assemblyBiochemistrytriglyceride-rich lipoproteinssymbolslipids (amino acids peptides and proteins)LipoproteinChylomicronInherited disorder
researchProduct

A practical method to determine the "atherogenic lipoprotein phenotype"

2008

aterosclerosilipoproteins methodology
researchProduct

Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia

2020

Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.

bempedoic acidmedicine.medical_specialtyStatinmedicine.drug_classHyperlipidemiasFamilial hypercholesterolemia030204 cardiovascular system & hematologyLipid-lowering therapystatins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansDicarboxylic AcidsIn patient030212 general & internal medicineHypolipidemic AgentsClinical Trials as Topiclipid-lowering therapyCholesterolbusiness.industryFatty Acidsnutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaselow-density lipoproteinchemistryDrug Therapy Combinationlipids (amino acids peptides and proteins)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsatherosclerosisCardiology and Cardiovascular MedicinebusinessBempedoic acidLipoproteinCoronary Artery Disease
researchProduct

Novel anti-obesity drugs and plasma lipids

2014

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceriderich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia ® , …

business.industryEndocrinology Diabetes and MetabolismTherapeutic effectPharmacologymedicine.diseaseObesityanti-obesity drugs contrave dyslipidemia lorcaserin low-density lipoprotein obesity Qsymia® triglycerideLorcaserinOrlistatPharmacotherapymedicineRisk factorCardiology and Cardiovascular MedicineAdverse effectbusinessDyslipidemiamedicine.drug
researchProduct

Estudio del defecto familiar de unión de la apolipoproteína B100 en una población mediterránea

2004

Fundamento y objetivo Comparar las caracteristicas clinicobioquimicas del defecto familiar de union de la apolipoproteina B100 (DFB) con la hipercolesterolemia familiar (HF) heterocigota en una poblacion mediterranea del sur de Europa donde existen pocos datos al respecto, estudiar la prevalencia y el posible efecto fundador del DFB en una zona de la Comunidad Valenciana y conocer las caracteristicas clinicobioquimicas del DFB. Sujetos y metodo Hemos estudiado a 19 heterocigotos con DFB (8 varones) pertenecientes a 12 familias, portadores de la mutacion R3500Q del gen de la apolipoproteina B, y a 57 heterocigotos con HF (24 varones) geneticamente caracterizados, seleccionados de forma aleat…

business.industryMedicineGeneral MedicineApolipoproteins bbusinessHumanitiesMedicina Clínica
researchProduct